Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News
Several factors may drive recent improvements in allo-HCT outcomes
Patients transplanted in recent years were older and sicker at baseline but had better outcomes than did patients transplanted in the mid-2000s....
News
Cardiovascular risks associated with cannabis use
Review authors suggest cardiovascular patients may benefit from cannabis screening and testing.
News
Travelers to three U.S. airports to be screened for novel coronavirus
People traveling from Wuhan, China, to New York (JFK), San Francisco (SFO), and Los Angeles (LAX) airports will be screened for symptoms...
News
BET inhibitor exhibits activity in myelofibrosis
ORLANDO - Responses were best among transfusion-dependent patients who received CPI-0610 and ruxolitinib.
News
NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomas
The guidelines include recommendations for managing pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
News
9/11 responders show increased risk of leukemia, other cancers
This is the first study to show that 9/11 responders have a higher incidence of leukemia than the general population.
Article
Researchers win funding for breast cancer studies
Five breast cancer researchers have won up to $1.4 million in funding from the National Comprehensive Cancer Network and Pfizer.
News
Score predicts locoregional recurrence of breast cancer
Postmenopausal patients with node-positive breast cancer were more likely to have locoregional recurrence if they had intermediate or high...
News
Adenotonsillectomy doesn’t improve cognitive function in preschoolers with OSA
There was no significant difference in global IQ at 12 months between patients who underwent adenotonsillectomy and those who did not.
News
Navitoclax may overcome ruxolitinib resistance in MF
ORLANDO – Navitoclax plus ruxolitinib decreased spleen volume, reduced bone marrow fibrosis, and improved total symptom scores in patients with...
News
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...
Article
Moffitt announces new chief digital innovation officer
Plus, a clinical trials expert joins St. Jude, ISGIO names a new president-elect, and ASCO gets a new board member.
News
Data support maintenance in metastatic colorectal cancer
Maintenance treatment improved progression-free survival, but not overall survival, compared with observation.
News
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients
ORLANDO – All 10 patients responded to anti-BCMA CAR T-cell therapy, including 3 patients who had previously failed BCMA-directed therapy.